Loading...
•
Sep 30, 2022
Harmony Biosciences Q3 2022 Earnings Report
Harmony Biosciences reported strong third-quarter performance driven by WAKIX demand and progress in clinical programs.
Key Takeaways
Harmony Biosciences reported a strong third quarter with net product revenues of $117.2 million, a 45.2% increase compared to the same period in 2021. GAAP net income was $87.9 million, or $1.44 per diluted share, compared to a GAAP net loss of $9.6 million, or ($0.17) per diluted share, for the same period in 2021. The company is encouraged by positive data from the PWS Phase 2 study and progress in clinical programs.
Net product revenues for Q3 2022 were $117.2 million, compared to $80.7 million for the same period in 2021, a 45.2% increase.
Average number of patients on WAKIX increased to approximately 4,600 for the quarter ended September 30, 2022.
GAAP net income for the quarter was $87.9 million, or $1.44 per diluted share, compared to a GAAP net loss of $9.6 million, or ($0.17) per diluted share, for the same period in 2021.
Non-GAAP adjusted net income was $58.1 million, or $0.95 per diluted share, for the quarter ended September 30, 2022, compared to Non-GAAP adjusted net income of $23.4 million, or $0.41 per diluted share, for the same period in 2021.
Revenue by Segment
Forward Guidance
The press release does not contain any forward guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...